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Introduction {#sec1}
============

Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of blastocysts, which are early-stage preimplantation embryos. ESCs have the ability to remain pluripotent and self-renew or to differentiate into multiple cell lineages. ESC identity and subsequent differentiation are controlled by intricate networks of transcription factors and signaling pathways that drive precise gene expression programs. Diverse chromatin regulators play important roles in these networks ([@bib13], [@bib39]), but the roles of specific histone modifying enzymes in ESC self-renewal or lineage specification are poorly understood.

GCN5 was the first histone lysine acetyltransferase (HAT) to be linked to active gene transcription ([@bib10]). GCN5 functions within multimember protein complexes, including SAGA and ATAC in multicellular organisms, to coactivate transcription ([@bib3], [@bib32], [@bib62]). In yeast, Gcn5-containing complexes are recruited to target genes via interactions with specific DNA-binding factors, but only a few such partners, such as cMYC and nMYC, have been defined in mammalian cells ([@bib24], [@bib44], [@bib75]). SAGA has also been suggested to act as a general transcription factor in yeast, widely enhancing expression of active genes ([@bib4], [@bib8]).

Genetic studies in mice revealed that both GCN5 and its catalytic activity are essential for normal development and embryo survival. *Gcn5*^*−/−*^ embryos die soon after gastrulation and exhibit increased apoptosis in mesodermal lineages ([@bib70]). *Gcn5* catalytic mutant mice survive until mid-gestation but develop cranial neural tube closure defects ([@bib11]) due to abnormal retinoic acid signaling involving a nonhistone substrate of GCN5 ([@bib68]). These findings indicate that GCN5-containing complexes have both HAT-dependent and -independent functions in early development. The phenotypes of *Gcn5* mutant mice also support a selective role for this HAT in gene regulation, as loss of general transcription factors often leads to early lethality prior to embryo implantation ([@bib63]).

Our previous studies defined GCN5 as an important coactivator for MYC and E2F family transcription factors in the regulation of cell-cycle genes involved in ESC self-renewal ([@bib24]) and pointed to the involvement of GCN5 in early ESC differentiation ([@bib41]). However, early developmental processes and associated signaling pathways modulated by GCN5 have not yet been defined.

Fibroblast growth factor (FGF) signaling is required for multiple stages of early embryonic development, from segregation of trophectoderm and primitive endoderm from the ICM ([@bib12], [@bib20], [@bib30], [@bib71]) to specification of primitive ectoderm and the primitive streak ([@bib14]), which in turn determine the fate of epiblast. ESC-based studies indicate that FGF signaling is involved in both pluripotency maintenance and lineage specification *in vitro* ([@bib33], [@bib37], [@bib73]). However, how epigenetic factors contribute to FGF-mediated gene regulation during early development is unclear.

Here, we use ESCs bearing a floxed allele of *Gcn5* to define GCN5 functions in embryoid body (EB) differentiation. Morphological and molecular analyses of *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs reveal an important role for GCN5 in the regulation of FGF signaling during early differentiation of EBs and confirm the importance of GCN5 for proper expression of select MYC target genes.

Results {#sec2}
=======

*Gcn5* Loss Leads to Epiblast Disorganization *In Vitro* {#sec2.1}
--------------------------------------------------------

The early lethality of *Gcn5*^*−/−*^ embryos poses challenges for detailed molecular studies, so we developed ESCs that carry a floxed allele of *Gcn5* ([@bib24]) to define pathways regulated by GCN5 during ESC differentiation *in vitro*. Before Cre-mediated recombination, the *Gcn5* floxed allele behaves as wild-type, and mice homozygous for this allele (*Gcn5*^*fx/fx*^) show no overt phenotypes ([@bib42]). After Cre exposure, exons 3--18 of *Gcn5* are deleted, creating a null allele (*Gcn5*^*−/−*^).

ESCs readily aggregate when cultured in suspension without inhibitors of differentiation (leukemia inhibitory factor \[LIF\] and 2i) and undergo stepwise morphological changes to form distinct three-dimensional structures. Hallmark events of this process include visceral endoderm differentiation (VE) and basement membrane (BM) assembly (days 2--3), followed by polarized epiblast formation from the inner cells and the clearance of a central cavity (days 4--6) ([@bib40]). These sequential events recapitulate transitions from formation of the ICM through embryonic gastrulation, thereby providing opportunities to define molecular events *in vitro* that might contribute to the death of *Gcn5*^*−/−*^ embryos shortly after gastrulation *in vivo* ([@bib70]).

We initially observed that *Gcn5*^*−/−*^ EBs were much smaller than *Gcn5*^*fx/fx*^ EBs at day 9, when all three germ layers should be formed ([Figure 1](#fig1){ref-type="fig"}A). However, at day 3, *Gcn5*^*−/−*^ EBs were not obviously different from controls. By day 5, *Gcn5*^*−/−*^ EBs began to suffer more breakage than the control EBs ([Figure 1](#fig1){ref-type="fig"}A), suggesting that null EBs were structurally fragile or that they were in the process of dying. However, cleaved Lamin A levels were not increased in day 5 *Gcn5*^*−/−*^ EBs ([Figure S1](#mmc1){ref-type="supplementary-material"}A), indicating that *Gcn5* loss did not induce apoptosis. Immunoblots of H3S10p ([Figure S1](#mmc1){ref-type="supplementary-material"}A), a marker for mitotic cells, also indicated that deletion of *Gcn5* did not inhibit cell proliferation. Global levels of H3K9ac were comparable in *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs at day 5 ([Figure S1](#mmc1){ref-type="supplementary-material"}B), consistent with the presence of other HATs (e.g., PCAF) in the EBs. Together these data indicate that GCN5 is required for normal morphology, but not proliferation or survival, in early stages of EB differentiation.Figure 1Loss of *Gcn5* Leads to Disorganization of Epiblast Cells during Early Differentiation(A) Bright-field images of differentiating EBs at days 3, 5, and 9, comparing EB morphology between *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs. Scale bar, 200 μM.(B and C) Representative immunofluorescence/confocal images of EB architecture in day 5 *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs, with (B) Laminin (red) staining for BM and (C) GATA4 (green) staining for VE, and SOX1 (magenta) and DAPI (blue) staining for nuclei of the epiblast. Scale bars, 100 μM in (B) and 50 μM in (C).See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To investigate whether the abnormal morphology of *Gcn5*^*−/−*^ EBs reflects defective formation of VE or BM at day 5, we performed immunostaining of GATA4 (for VE) and Laminin (for BM). Since a majority of the inner cells express early neuroectodermal markers by day 5, we also used immunostaining of SOX1 to visualize the organization of epiblast cells. Laminin staining of the BM showed little difference between the null and control EBs ([Figure 1](#fig1){ref-type="fig"}B). GATA4 staining was also very similar in *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs, indicating normal formation and organization of the VE ([Figure 1](#fig1){ref-type="fig"}C). In contrast, SOX1 staining revealed severe disorganization of the columnar epithelial morphology of the epiblast in *Gcn5*^*−/−*^ EBs, indicating that GCN5 is required for normal epiblast formation and organization.

Compromised Differentiation Potential of *Gcn5* Null EBs {#sec2.2}
--------------------------------------------------------

The epiblast gives rise to all three germ layers ([@bib51]), so we asked whether *Gcn5* loss affects lineage differentiation. We examined marker genes that normally exhibit peak expression in the embryonic epiblast, including *Fgf5* and *Otx2* ([@bib29], [@bib35], [@bib59], [@bib71]), and confirmed lower expression levels in the null epiblasts at day 5 ([Figure 2](#fig2){ref-type="fig"}A). We then used mass cytometry to more fully assess the composition of cell populations within the control and null EBs ([@bib6]) ([Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). Day 5 EBs were dissociated and stained with antibodies specific for markers for either pluripotent cells or germ layer progenitors ([Table S1](#mmc1){ref-type="supplementary-material"}). The antibodies were labeled with nonradioactive isotopes of rare earth metals with distinct atomic masses, which are distinguished by mass cytometry and serve as reporters for the labeled cells. This approach allowed us to delineate multiple lineages simultaneously and compare the compositions of heterogeneous populations in day 5 EBs. SPADE (spanning-tree progression analysis of density-normalized events) analysis was used to visualize and categorize populations based on combinatorial marker expression ([Table S1](#mmc1){ref-type="supplementary-material"}) and to quantify the mass cytometry data. The results indicated that *Gcn5*^*−/−*^ EBs contained significantly lower numbers of endodermal and mesodermal cells relative to *Gcn5*^*fx/fx*^ EBs, whereas comparable numbers of cells were observed for pluripotent populations ([Figures 2](#fig2){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Decreased mesoderm populations in the *Gcn5*^*−/−*^ EBs were confirmed across four replicate experiments ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). The ectoderm population in the null EBs was unchanged in cell number ([Figure 2](#fig2){ref-type="fig"}B, right), although the ectoderm region in the SPADE tree showed changes in some nodes ([Figure 2](#fig2){ref-type="fig"}B, left), likely due to specificity limitations of the antibodies used to define ectoderm ([Figure S2](#mmc1){ref-type="supplementary-material"}). Decreased expression of all germ layer markers was observed in late-stage *Gcn5*^*−/−*^ EBs (days 9 and 12) ([Figure 2](#fig2){ref-type="fig"}C), likely stemming from the earlier defects observed at day 5.Figure 2Compromised Differentiation Potentials of *Gcn5* Null EBs(A) Gene expression analysis by quantitative real-time PCR for epiblast marker genes.(B) Changes in population composition in *Gcn5* null EBs at epiblast stage. Left: SPADE tree plot showing decreased endoderm and mesoderm populations in the *Gcn5* null EBs at day 5; Right: quantitation of fold changes in cell numbers of a given population in *Gcn5* null EBs relative to control.(C) Quantitative real-time PCR plots showing decreased expression of marker genes for ectoderm (*Sox1, Cdh2*), endoderm (*Foxa2, Gata6*), and mesoderm (*T*) in late-stage EBs (days 9 and 12).Data are presented as means ± SD from three (A and C) or four (B) independent experiments.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

To further confirm the effects of *Gcn5* loss on mesoderm and endoderm formation, we utilized a monolayer differentiation protocol to direct ESCs toward these lineages ([@bib65]). Again we observed significantly decreased expression of mesoderm-specific genes (*T*, *Flk1,* and *Pdgfrb*), but in contrast to the results in EBs, expression of endoderm-specific genes was unaffected (*Gata4*) or upregulated (*Sox17* and *FoxA2*) in *Gcn5*^*−/−*^ cells differentiated in monolayer ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Altogether these results indicate that GCN5 is most important for mesoderm formation during ESC differentiation, reminiscent of our previous findings in *Gcn5*^*−/−*^ embryos ([@bib70]).

Expression Profiling Reveals a Regulatory Role for GCN5 in FGF Signaling {#sec2.3}
------------------------------------------------------------------------

GCN5 acts as a transcriptional coactivator in the context of the SAGA and ATAC complexes ([@bib32], [@bib57], [@bib58]). To better understand the molecular basis underlying the defects caused by *Gcn5* loss, we performed RNA sequencing (RNA-seq) to compare gene expression profiles in day 3 and day 5 control and null EBs. Total RNA from three technical replicates of *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs were sequenced, and key gene expression changes were confirmed using a second biological replicate (EBs generated from a separate matched pair of *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ ESCs) by quantitative real-time polymerase chain reaction (PCR). These time points were chosen to define both early events (day 3) and events that coincide with the onset of the abnormal phenotype of *Gcn5*^*−/−*^ EBs (day 5).

Principal component analysis revealed significant differences in gene expression profiles between day 3 and day 5 EBs, consistent with developmental progression over time. Of note, differences in the gene expression profiles between null and control EBs were less pronounced at day 3 than at day 5 ([Figure 3](#fig3){ref-type="fig"}A), with 754 genes exhibiting altered expression in day 5 null EBs, whereas 158 genes were affected in day 3 nulls ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These data indicate that *Gcn5* loss more significantly affects gene expression programs at day 5, consistent with the timing of the onset of *Gcn5* null morphological phenotype. Therefore, we focused further detailed analyses on differences in gene expression observed at day 5.Figure 3Expression Profiling Points to a Regulatory Role of *Gcn5* in FGF Signaling in Day 5 EBs(A) Principal component analysis plots showing variance of expression profiles among replicative samples and increased differences in profiles between *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs at day 5 compared with day 3 (*n* = 3).(B) Example gene set enrichment analysis enrichment plots showing top processes enriched in the control EBs compared with *Gcn5*^*−/−*^ EBs at day 5. Color code: red, positively correlated with *Gcn5*^*fx/fx*^; blue, negatively correlated with *Gcn5*^*−/−*^.(C) Significantly altered pathways in the day 5 *Gcn5* null EBs identified by IPA canonical pathway analysis.(D) Quantitative real-time PCR validating the key genes in the FGF signaling identified by the RNA-seq using a second biological sample. Data are presented as means ± SD from three independent experiments.FDR, false discovery rate; NES, normalized enrichment score. See also [Figure S4](#mmc1){ref-type="supplementary-material"}, [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Gene set enrichment analysis revealed significant downregulation of several biological processes in the null EBs at day 5, with multicellular organismal development (MOD) and cell surface receptor linked signal transduction (CSRLST) among the most affected ([Figure 3](#fig3){ref-type="fig"}B). In the MOD category, 15 of 50 genes were among the core enrichment group in the null EBs, including *Pax5, Msx2, Gli1, Spry2*, and *Mest*, which are all important for early development or ESC differentiation ([@bib38], [@bib60], [@bib61], [@bib64], [@bib69]) ([Figure S4](#mmc1){ref-type="supplementary-material"}B and [Table S2](#mmc1){ref-type="supplementary-material"}). In the CSRLST category, 7 of 30 genes were in the core enrichment group, including *Grb10*, the most downregulated gene in the null EBs ([Figure S4](#mmc1){ref-type="supplementary-material"}C and [Table S3](#mmc1){ref-type="supplementary-material"}). Consistent with these results, Ingenuity Pathway Analysis (IPA) identified a number of signaling pathways to be significantly altered in the null EBs. Interestingly, four of the seven top-ranked affected pathways were intimately linked to FGF signaling, including regulation of epithelial-to-mesenchymal transition, STAT3, FGF, and growth hormone signaling pathways ([Figure 3](#fig3){ref-type="fig"}C).

FGF ligands and their receptor tyrosine kinases control multiple developmental processes, including cell proliferation, survival, differentiation, and migration ([@bib9]). We confirmed that expression of key genes in the FGF pathway, including *Fgf3, Fgf4,* and *Spry4*, was altered in the *Gcn5*^*−/−*^ EBs using quantitative real-time PCR. We also confirmed that *Grb10*, an effector of insulin signaling ([@bib16], [@bib74]), was strongly downregulated. Conversely, effector genes such as *Stat3* and *Prkca* were upregulated ([Figure 3](#fig3){ref-type="fig"}D).

Connections between Defective FGF Signaling and Morphological Abnormalities of *Gcn5*^*−/−*^ EBs at Day 5 {#sec2.4}
---------------------------------------------------------------------------------------------------------

To link the above changes in gene expression to the status of FGF signaling intermediates in *Gcn5*^*−/−*^ EBs, we examined levels of FGFR1 and phosphorylation of ERK, p38, c-RAF, and AKT by immunoblotting ([Figures 4](#fig4){ref-type="fig"}A and 4B). FGFR1 protein levels and activated, phosphorylated forms of both ERK and p38 (P-ERK and P-p38, respectively) were notably decreased in *Gcn5*^*−/−*^ EBs, indicating deficient activation of the RAS/MAPK pathway. In contrast, levels of activated AKT (P-AKT) and P-c-RAF-Ser259 were unchanged or slightly increased. Levels of phospholipase C-γ did not change (data not shown), even though *Prkca* mRNA was upregulated in the null EBs.Figure 4Abnormal Activities of the FGF Signaling Pathway in Day 5 *Gcn5*^*−/−*^ EBs(A) Representative immunoblots showing decreased phosphorylated forms of ERK and p38 in the *Gcn5* null EBs at day 5.(B) Representative immunoblots showing the AKT pathway is affected to a lesser degree in the null EBs at day 5.(C) Zeiss LSM 880 confocal Airyscan images showing disorganization of F-actin (red) and vimentin (green) in day 5 null EBs. Scale bars, 10 μM.(D) Representative immunoblots showing decreased vimentin in *Gcn5*^*−/−*^ EBs at day 5.

To relate these molecular changes back to the morphological phenotypes of the *Gcn5*^*−/−*^ EBs, we examined the organization of cytoskeletal components regulated by ERK and p38 signaling ([@bib26]) using Airyscan (Zeiss) laser-scanning confocal microscopy. We first assessed filamentous actin (F-actin) in day 5 EBs using phalloidin staining. In epiblasts of EBs or early embryonic epithelial structures, F-actin localizes to the periphery of epithelial cells and is particularly enriched at apical sites of columnar epithelial cells ([@bib43], [@bib52]). This staining pattern was observed as expected in *Gcn5*^*fx/fx*^ EBs. In contrast, *Gcn5*^*−/−*^ EBs displayed reduced apical distribution of F-actin, primarily in the inner cells (epiblast) ([Figure 4](#fig4){ref-type="fig"}C). Airyscan images of vimentin staining also indicated altered localization and decreased staining intensity of this intermediate filament protein in *Gcn5*^*−/−*^ EBs ([Figure 4](#fig4){ref-type="fig"}C). Depletion of vimentin was further confirmed by immunoblotting ([Figure 4](#fig4){ref-type="fig"}D). These findings suggest that insufficient activation of ERK and p38 upon *Gcn5* loss affects F-actin and vimentin organization during early differentiation, in concordance with disorganized epithelial architectures of the inner cell layer observed in the null EBs ([Figure 1](#fig1){ref-type="fig"}C). Defective ERK signaling is also consistent with decreased mesoderm differentiation ([@bib7]) in *Gcn5*^*−/−*^ EBs ([Figure 2](#fig2){ref-type="fig"}) and embryos ([@bib70]).

Decreased Gene Expression and Reduced H3K9ac at Gene Promoters Identified Likely Direct Targets of GCN5 {#sec2.5}
-------------------------------------------------------------------------------------------------------

To identify genes directly regulated by GCN5 in EBs at the epiblast stage, we attempted chromatin immunoprecipitation sequencing (ChIP-seq), but we were not successful using either commercially available antibodies for GCN5 or a biotin-tagging system ([@bib24]) in differentiating ESCs. Since histone H3 lysine 9 (H3K9) is a well-characterized substrate for GCN5 ([@bib27], [@bib34]), we performed H3K9ac ChIP, using the same control and *Gcn5*^*−/−*^ EBs used for RNA-seq. We reasoned that localized decreases in H3K9ac in the *Gcn5*^*−/−*^ EBs might identify genes that uniquely require the presence of this HAT for proper regulation. As global levels of H3K9ac were not affected by *Gcn5* loss ([Figure S1](#mmc1){ref-type="supplementary-material"}B), regions identified by this approach will likely provide an underestimate of GCN5 targets due to redundancies with PCAF and possibly other HATs.

We identified 173 H3K9ac peaks that were decreased in the *Gcn5*^*−/−*^ EBs, the majority (154) of which were located near gene promoters. Gene annotation identified 238 genes likely driven by these promoters, with occasions where H3K9ac peaks fell in putative promoter regions associated with more than one gene. We also uncovered 144 H3K9ac peaks that increased upon *Gcn5* loss, yet only 30 of those peaks were near the promoters, associated with 31 genes. These data are consistent with the gene-specific coactivator role of GCN5 in gene transcription ([Figure 5](#fig5){ref-type="fig"}A). Comparison of genes identified in our analyses as having decreased H3K9ac promoter peaks with ENCODE ChIP-seq data ([@bib2]) identified candidate transcription factors that might recruit GCN5 to these regions ([Table S4](#mmc1){ref-type="supplementary-material"}). Top TFs identified by this approach include HCFC1 (Q value 1.25 × 10^−77^), a nuclear protein known to associate with GCN5-containing complexes ([@bib66]), as well as TBP (Q value 1.69 × 10^−59^) and CTCF (Q value 3.77 × 10^−59^). Strikingly, a number of MYC family members, including MAX, MXI1, and cMYC, were also identified by this approach, consistent with our previous work connecting GCN5 to MYC functions in both ESCs and during somatic cell reprogramming.Figure 5Identification of Direct GCN5 Target Genes at the Early Stage of Differentiation(A) Comparing profiles of H3K9ac peaks and associated genes in *Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ EBs at day 5. Loss of *Gcn5* resulted in decreased H3K9ac peaks mostly in the promoter region. Most of the genes (238 of 269) with altered H3K9ac peaks exhibited a decreased level of this mark.(B) Putative target genes directly regulated by GCN5. Venn diagram showing overlap between H3K9ac decreased genes and GCN5 induced genes. Overlapping genes are listed in the table with a general description of the reported functions.(C) Examples of H3K9ac peak profiles (n = 4) and RNA transcripts (n = 3) for top targets of GCN5 in day 5 EBs. RNA transcript levels are presented as means ± SD.(D) Representative immunoblots showing reduced levels of cMYC isolated from nuclei of day 5 *Gcn5*^*−/−*^ EBs. NE, nuclear extracts.(E) ChIPs for MYC reveal decreased MYC binding at the promoters of GCN5 target genes in day 5 *Gcn5*^*−/−*^EBs. Enrichment of MYC relative to input at each locus is presented as the mean ± SD from three independent experiments.See also [Table S4](#mmc1){ref-type="supplementary-material"}.

To better determine which of these regions might reflect genes directly activated by GCN5, we compared genes with decreased H3K9ac at their promoters with genes identified as downregulated more than 2-fold by RNA-seq. Only seven genes were both downregulated and decreased in H3K9ac. Three of these genes, *Grb10*, *Gldc*, and *Nmnat*, further reinforce the link among GCN5, metabolism, and signaling ([Figures 5](#fig5){ref-type="fig"}B and 5C). The other four genes (*Rps6ka2*, *Mthfd2*, *Bcat1*, and *Srm*) are directly regulated by cMYC ([@bib5], [@bib49], [@bib56]) ([Figure 5](#fig5){ref-type="fig"}B). *Myc* is induced by most mitogenic factors, including FGFs ([@bib23]). We observed decreased cMYC protein levels upon loss of *Gcn5* ([Figure 5](#fig5){ref-type="fig"}D), consistent with a previous report in a different cellular system ([@bib48]). ChIP-qPCR confirmed MYC recruitment to the promoter regions of *Rps6ka2*, *Mthfd2*, and *Bcat1* in *Gcn5*^*fx/fx*^ EBs and loss of MYC from these regions in *Gcn5*^*−/−*^ EBs at day 5 ([Figures 5](#fig5){ref-type="fig"}C and 5E). These findings further highlight the GCN5-MYC partnership in gene regulation during early differentiation of EBs.

Discussion {#sec3}
==========

Our findings reveal that loss of *Gcn5* strongly affects FGF signaling at multiple levels during early differentiation of EBs, with decreased expression of *Fgf*s and FGFR1 and deficient activation of ERK and p38. Moreover, *Gcn5* loss leads to direct downregulation of specific genes involved in signaling and metabolism as well as discrete MYC gene targets ([Figure 6](#fig6){ref-type="fig"}).Figure 6GCN5 Affects Multiple Components of the FGF Signaling Pathway and Activates Selective Targets during Early DifferentiationTop: the abnormal phenotype of *Gcn5*^*−/−*^ EBs becomes evident early during EB differentiation (day 5). Loss of *Gcn5* leads to disorganization of the epiblast architecture that is associated with defective cytoskeleton networks (F-actin and vimentin) and decreases in progenitors fated for mesoderm. At later stages of differentiation (days 9 and 12), *Gcn5*^*−/−*^ EBs are smaller in size and express lower levels of marker genes for ectoderm (blue), endoderm (green), and mesoderm (magenta), compared with the controls. Lighter shades indicate decreased expression levels of marker genes for each population. Middle: at day 5, GCN5 affects expression of multiple genes encoding critical components in FGF signaling and for proper activation of ERK and p38 pathways. Solid diamond, up (red) or down (green) regulated transcripts; open diamond (green), decreased protein expression; double open diamond (green), decreased protein phosphorylation. Bottom: at day 5, GCN5 is required for activation of genes important for signaling through promoter-associated H3K9ac, including four cMYC targets (blue).

FGF signaling regulates both migration and patterning of mesoderm during gastrulation ([@bib14]). Failures in the execution of this pathway are consistent with the abnormal cytoskeletal organization and defective mesoderm formation observed in *Gcn5*^*−/−*^ EBs. In addition, identification of *Bcat1*, *Rps6ka2*, *Mthfd2*, and *Srm* as likely direct targets of GCN5, which exhibit decreased expression upon *Gcn5* loss along with reduced MYC binding and diminished H3K9ac at their promoters, provides further evidence that GCN5 is an important coactivator for MYC during early differentiation. These genes are known to be immediate-response, MYC target genes induced by FGF signaling.

Another notable common function of the direct targets of GCN5 identified here is that they regulate metabolism and growth downstream of AKT and/or ERK signaling, either positively (*Nmnat2*, *Bcat1*, *Gldc*, *Mthfd2*, and *Srm*) or negatively (*Grb10*, *Bcat1*, and *Rps6ka2*) ([Figure 5](#fig5){ref-type="fig"}B) ([@bib21], [@bib47], [@bib49], [@bib53], [@bib54], [@bib55], [@bib74]). Altered carbon metabolism induced by these gene expression changes could further derail differentiation ([@bib19], [@bib25]).

In addition to histones, GCN5 acetylates nonhistone proteins that may indirectly regulate gene transcription or function outside of gene regulation ([@bib15], [@bib28], [@bib68]). For example, GCN5 pairs with MYC-nick, a CALPAIN-cleaved cytoplasmic derivative of MYC, to acetylate alpha-tubulin (ac-αTUB) and to regulate cytoskeleton organization and differentiation of myoblasts ([@bib15]). We found that total ac-αTUB levels in *Gcn5* null EBs at day 5 were unchanged (data not shown), but we cannot exclude contributions of changes in acetylation of other targets to the developmental phenotypes we observe.

Our previous genetic studies showed that *Gcn5*^*−/−*^*;Pcaf*^*−/−*^ embryos die earlier than *Gcn5*^*−/−*^ embryos, even though *Pcaf* deletion on its own causes no abnormal phenotype ([@bib70], [@bib72]). These findings indicate that *Gcn5* and *Pcaf* have shared functions during early development. The lack of global changes in H3K9ac and limited changes in H3K9ac at gene promoters observed in day 5 *Gcn5*^*−/−*^ EBs is consistent with functional redundancy with PCAF and possibly other HATs. Nonetheless, compensatory H3K9ac by PCAF did not prevent defective morphology and signaling in the early *Gcn5*^*−/−*^ EBs, suggesting that GCN5 and H3K9ac are uniquely required for regulation of specific genes during early differentiation.

GCN5 is most active *in vivo* when incorporated into SAGA and ATAC in mammals ([@bib32], [@bib66]). Our studies do not differentiate the functions of the two complexes, and the phenotypes we observe may reflect loss of activity of both. However, knockout of *Atac2,* a component of ATAC but not SAGA, did not cause defects in lineage differentiation ([@bib58]), as was observed in *Gcn5*^*−/−*^ embryos, suggesting SAGA may be most important for these early developmental events.

Interestingly, more genes were upregulated upon loss of *Gcn5* (at both days 3 and 5) than were downregulated, in contrast to the role of GCN5 as a coactivator of transcription. Many of these events are likely indirect effects of *Gcn5* loss, although we cannot exclude the possibility that GCN5 may be involved in gene repression during early differentiation. Indeed, a recent study revealed that another HAT, TIP60, acts as a transcriptional repressor in ESCs ([@bib18]). Notably, many of the genes upregulated upon *Gcn5* loss are involved in acute phase response and interferon signaling (data not shown), consistent with our previous work in fibroblasts that indicated GCN5 and PCAF repress interferon-β expression by targeting a nonhistone substrate, TBK1 ([@bib28]).

Abnormal regulation of growth-factor-driven pathways drive oncogenesis ([@bib22]). Our findings here suggest that GCN5 may also be important in cancers associated with deregulation of FGFs. Future work will explore this possibility, as well as the therapeutic potential of targeting GCN5 to inhibit growth or progression of these cancers.

Experimental Procedures {#sec4}
=======================

ES Cell Culture and Differentiation {#sec4.1}
-----------------------------------

*Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^ ESC lines were generated and characterized previously ([@bib24]). ESCs were routinely grown on gelatin-coated plates in Dulbecco's modified Eagle's medium (DMEM)/high glucose (HyClone, SH3002201) medium supplemented with 15% (v/v) ESC-screened fetal bovine serum (HyClone, SH3007003E), 2 mM L-glutamine (HyClone, SH3003401), 0.1 mM nonessential amino acids (Corning, MT25025CI), 1% (v/v) penicillin/streptomycin (HyClone, SV30010), 0.1 mM β-mercaptoethanol (BME) (Fisher, 03446I-100), 1000 U/mL LIF/ESGRO (Millipore, ESG1107), 1 μM PD0325901 (Sigma, PZ0162) and 3 μM 1-azakenpaullone (Sigma, A3734), and passaged every 2--3 days.

For EB differentiation, 3 × 10^5^ cells/well were plated in ultra-low attachment six-well plates in differentiation medium without LIF or 2i-s. Media were replaced every other day by settling the EBs at low speed centrifugation (100 × *g* for 1 min). The differentiation medium was DMEM/high glucose:F12 (Cellgro, MT10080CV):neurobasal medium (Gibco, 21103049) (1:1:2) supplemented with 10% KnockOut Serum Replacement medium (Gibco, A3181502), 2 mM L-glutamine, 1% (v/v) penicillin/streptomycin, and 0.1 mM BME.

Immunofluorescence and Confocal Imaging {#sec4.2}
---------------------------------------

EBs were washed once in PBS/1% BSA and fixed in 4% paraformaldehyde (PFA) for 30 min at room temperature. The fixed EBs were incubated in 7.5% sucrose/PBS for at least 1 hr at room temperature, then in 15% sucrose/PBS at 4°C overnight. The EBs were then embedded in Tissue-Tek OCT compound (Electron Microscopy Sciences, 62550-12) and incubated for 10 min at room temperature with agitation before they were frozen in liquid nitrogen (LN2). Frozen sections (8 μM) were fixed in 2% PFA for 2 min then blocked with PBS containing 0.1% Tween 20 (Fisher, BP337-500) (PBT) and 5% normal donkey serum (Millipore, S30-100ML) for 30 min at room temperature. The blocked sections were incubated with primary antibodies diluted in blocking buffer overnight at 4°C. The slides were washed with PBT three times for a total 15 min, followed by incubations with fluorescence-conjugated secondary antibodies for 40 min at room temperature. DAPI staining was performed after washing off the secondary antibodies. The slides then were washed with PBT and mounted with coverslips using ProLong Gold Antifade mounting medium (Invitrogen, P36930). The slides were imaged on a Zeiss LSM 880 laser-scanning microscope. Airyscan detector array was used to image the cytoskeletons. Standard pinhole was used to image the markers for lineages, proliferation, and apoptosis. The antibodies used are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Expression Analysis {#sec4.3}
-------------------

EBs were harvested and total RNA was isolated using an RNeasy mini plus kit (QIAGEN, 74134) following the manufacturer\'s instructions. Total RNA (10--20 ng) was used per reaction, and quantitative real-time PCRs were performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, 4351107) using the Power SYBR Green RNA-to-CT1-Step Kit (Life Technologies, 4389986). Three technical replicates were performed for each gene target tested and *Pbgd* was used as a reference gene for quantification. A two-tailed Student's t test was used for pairwise comparisons. Primers used are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA Sequencing {#sec4.4}
--------------

Total RNA libraries were prepared from three independent experiments using the Illumina TruSeq stranded total RNA kit according to the manufacturer\'s protocol, except that the PCR amplification was reduced to eight cycles. Each library (10 pM) was sequenced on an Illumina HiSeq 2500. The reads were mapped to the mouse genome (mm10) by TopHat (version 2.0.10) ([@bib31]) with an overall mapping rate of 84%--94%. DESeq ([@bib1]) was used for differential gene expression analysis. Details of RNA-seq analysis are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP, qPCR, and Deep Sequencing {#sec4.5}
-------------------------------

Day 5 EBs (*Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^) were washed once with PBS and dissociated using Accutase cell dissociation reagent (Gibco, A1110501). ChIPs were performed as previously described ([@bib67]) with modifications in chromatin sonication. Details are included in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

qPCRs were performed on a 7500 Fast Real-Time PCR System using ChIP DNA from three replicative experiments and Power SYBR Green PCR Master Mix (Life Technologies, 4367659). Student's t test was used for pairwise comparisons. Primers used are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP DNA from four independent experiments, including two replicates for each isolate pair (*Gcn5*^*fx/fx*^ and *Gcn5*^*−/−*^), were used for deep sequencing. Detailed ChIP library preparations are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Each library (10 pM) was sequenced on an Illumina HiSeq 3000. Raw reads were aligned to mouse genome mm10 using bowtie (version 1.1.2) ([@bib36]). H3K9ac peaks were called by MACS (version 1.4.2) ([@bib76]) using H3 as control. Detailed ChIP-seq data analysis is included in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Mass Cytometry and Data Analysis {#sec4.6}
--------------------------------

Sample preparation for mass cytometry was performed as previously described ([@bib45]). Briefly, EBs were dissociated using Accutase, stained with cisplatin for viability at 25 μM for 1 min at room temperature, then quenched using PBS containing 1% BSA. The cells were fixed in 1.5% PFA for 10 min at room temperature, then permeabilized with methanol (1 mL per million cells) and incubated overnight at 4°C. Samples were barcoded ([@bib46]), pooled, and immunostained with the panel of antibodies shown in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Cells were stained with 1:2000^191/193^ iridium (Ir) DNA intercalator (Fluidigm), 62.5 nM final, for 10 min at room temperature. The samples were combined with EQ Four Element Calibration Beads (Fluidigm) then diluted with water to a concentration of 5 × 10^5^ cells/mL and run at 45 μL/min on a CyTOF 2 mass cytometer (Fluidigm). Data were normalized on bead passport using CyTOF software (v6.0.626; Fluidigm).

Initial data processing and gating was done with FlowJo vX10.0. EQ Four Element Calibration Beads were removed, and data were gated on singlets by Ir193 and Event Length parameters. Removal of dead cells was done in the Pt198 channel. SPADE analysis of the data was performed using SPADE V3.0 ([@bib50]) in MATLAB r2015b (Mathworks). SPADE tree construction was performed using agglomerative clustering on all markers listed in [Table S1](#mmc1){ref-type="supplementary-material"}. Annotation of SPADE tree regions was done according to marker distribution as shown in [Figure S2](#mmc1){ref-type="supplementary-material"}, and cell percentages in each region were calculated for all samples. Percentages were normalized relative to mean *Gcn5*^*fx/fx*^, and statistical significance was determined by the Wilcoxon rank-sum test performed in MATLAB using the ranksum function.

Immunoblotting {#sec4.7}
--------------

Whole-cell lysates (WCL) were prepared from D5 EBs using RIPA buffer. Nuclear extracts (NEs) were prepared following the Dignam-Roeder protocol ([@bib17]). All buffers contained protease inhibitor cocktail (Sigma, P8340) and phosphatase inhibitor cocktail (Roche, 04906845001). WCL or NE (10--20 μg) was resolved on 4%--12% Bis-Tris protein gels (WG1402BOX). Proteins were transferred to nitrocellulose membranes (Invitrogen, IB23001) using an iBlot2 (Life Technologies, IB21001), then blocked and incubated with primary antibodies following standard procedures. Primary antibodies were detected with peroxidase-conjugated secondary antibodies (1:8,000) and Amersham ECL prime western blotting detection reagent (GE Healthcare, RPN2232) following the manufacturer\'s instructions. The antibodies used are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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Accession Numbers {#app1}
=================
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Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S4, and Tables S1--S4Document S2. Article plus Supplemental Information

This work was largely supported by NIH R01 grant GM067718 to S.Y.R.D. The Science Park NGS Core performed the deep sequencing supported by CPRIT Core Facility Support Grants RP120348 and RP170002. Bioinformatics was made possible in part by support from the MDACC Center for Cancer Epigenetics (CCE). Immunofluorescence/confocal analysis was performed at the Science Park IF/imaging core, partially supported by CCE. We thank Andrew Salinger (A.S.) and Amanda Martin for critical material support in the lab, Hsueh-Ping Chao for help in bioinformatics, and Yoko Takata and Luis Coletta for help in NGS. We appreciate A.S. and Dr. Lisa Mustachio for helpful comments on the manuscript.

Supplemental Information includes Supplemental Experimental Procedures, four figures, and four tables and can be found with this article online at [https://doi.org/10.1016/j.stemcr.2017.11.009](10.1016/j.stemcr.2017.11.009){#intref0015}.

[^1]: Co-first author

[^2]: Present address: Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104, USA

[^3]: Present address: National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
